Trials / Conditions / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome

19 registered clinical trials studyying Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome.

Status	Trial	Sponsor	Phase
Unknown	Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Ch NCT02071901	Case Comprehensive Cancer Center	Phase 2
Terminated	Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute My NCT02029417	Roswell Park Cancer Institute	Phase 2
Withdrawn	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Maligna NCT01652014	University of Medicine and Dentistry of New Jersey	Phase 2
Completed	Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treatin NCT01707004	University of Wisconsin, Madison	Phase 2
Terminated	Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission NCT01465386	Fred Hutchinson Cancer Center	Phase 2
Completed	Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating NCT01349972	National Cancer Institute (NCI)	Phase 2
Completed	Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Old NCT02085408	ECOG-ACRIN Cancer Research Group	Phase 3
Completed	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747	National Cancer Institute (NCI)	Phase 1
Completed	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388	Roswell Park Cancer Institute	N/A
Completed	Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT00795002	National Cancer Institute (NCI)	Phase 2
Completed	Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid L NCT00602771	National Cancer Institute (NCI)	Phase 2
Completed	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586	Case Comprehensive Cancer Center	Phase 2
Completed	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Bloo NCT00343798	Fred Hutchinson Cancer Center	Phase 1
Completed	Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrom NCT00331513	National Cancer Institute (NCI)	Phase 1
Completed	Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With NCT00322101	Fred Hutchinson Cancer Center	Phase 3
Completed	Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT00101296	National Cancer Institute (NCI)	Phase 1
Terminated	Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Le NCT00052598	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary A NCT00045435	Fred Hutchinson Cancer Center	Phase 2
Completed	Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia NCT00027872	National Cancer Institute (NCI)	Phase 2